Suzanne A. Eccles

Division of Cancer Therapeutics, The Institute of Cancer Research

Affiliated withThe Institute of Cancer Research

Research Area

Biography

Suzanne A. Eccles has not added Biography.
If you are Suzanne A. Eccles and would like to personalize this page please email our Author Liaison for assistance.

JoVE Journal Publications

ArticleTotal : 1	Year
Publication title Cited by 217	2015

Other Publications

Article	Year
Parallels in invasion and angiogenesis provide pivotal points for therapeutic intervention. The International journal of developmental biology\| PubMed ID: 15349833	2004
The role of c-erbB receptors and ligands in head and neck squamous cell carcinoma. Oral oncology\| PubMed ID: 12167415	2002
Use of plasma MMP-2 and MMP-9 levels as a surrogate for tumour expression in colorectal cancer patients. International journal of cancer. Journal international du cancer\| PubMed ID: 14520690	2003
Phosphoinositide 3-kinase signalling pathways in tumor progression, invasion and angiogenesis. Tumori\| PubMed ID: 15143962	2004
Signaling pathways required for matrix metalloproteinase-9 induction by betacellulin in head-and-neck squamous carcinoma cells. International journal of cancer. Journal international du cancer\| PubMed ID: 15197768	2004
Combination epidermal growth factor receptor inhibition and radical radiotherapy for NSCLC. Expert review of anticancer therapy\| PubMed ID: 15270661	2004
Targeting key steps in metastatic tumour progression. Current opinion in genetics & development\| PubMed ID: 15661537	2005
Breast cancer metastasis: when, where, how? Lancet\| PubMed ID: 15781080	2005
Biological significance of c-erbB family oncogenes in head and neck cancer. Cancer metastasis reviews\| PubMed ID: 15785872	2005
PLCgamma1 is essential for early events in integrin signalling required for cell motility. Journal of cell science\| PubMed ID: 15944397	2005
The phosphoinositide 3-kinase signalling pathway as a therapeutic target in squamous cell carcinoma of the head and neck. Expert opinion on therapeutic targets\| PubMed ID: 16083342	2005
Cell migration/invasion assays and their application in cancer drug discovery. Biotechnology annual review\| PubMed ID: 16216785	2005
Identification of magnetic resonance detectable metabolic changes associated with inhibition of phosphoinositide 3-kinase signaling in human breast cancer cells. Molecular cancer therapeutics\| PubMed ID: 16432178	2006
Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis. Molecular cancer therapeutics\| PubMed ID: 16546966	2006
The vascular targeting property of paclitaxel is enhanced by SU6668, a receptor tyrosine kinase inhibitor, causing apoptosis of endothelial cells and inhibition of angiogenesis. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 16551869	2006
The phosphoinositide-specific phospholipase C inhibitor U73122 (1-(6-((17beta-3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione) spontaneously forms conjugates with comm... Drug metabolism and disposition: the biological fate of chemicals\| PubMed ID: 17403917	2007
Metastasis: recent discoveries and novel treatment strategies. Lancet\| PubMed ID: 17512859	2007
Application of meso scale technology for the measurement of phosphoproteins in human tumor xenografts. Assay and drug development technologies\| PubMed ID: 17638539	2007
4,5-diarylisoxazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. Journal of medicinal chemistry\| PubMed ID: 18020435	2008
Plexin-B1 mutations in prostate cancer. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 18024597	2007
AACR-NCI-EORTC--19th symposium. Molecular Targets and Cancer Therapeutics--Part 4. IDrugs : the investigational drugs journal\| PubMed ID: 18041676	2007
The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 18056200	2007
An in vitro and in vivo study of the combination of the heat shock protein inhibitor 17-allylamino-17-demethoxygeldanamycin and carboplatin in human ovarian cancer models. Cancer chemotherapy and pharmacology\| PubMed ID: 18193424	2008
NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer research\| PubMed ID: 18413753	2008
CHR-2797: an antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer research\| PubMed ID: 18701491	2008
The identification of 2-(1H-indazol-4-yl)-6-(4-methanesulfonyl-piperazin-1-ylmethyl)-4-morpholin-4-yl-thieno[3,2-d]pyrimidine (GDC-0941) as a potent, selective, orally bioavailable inhibitor... Journal of medicinal chemistry\| PubMed ID: 18754654	2008
A microRNA DNA methylation signature for human cancer metastasis. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 18768788	2008
Molecular pharmacology of phosphatidylinositol 3-kinase inhibition in human glioma. Cell cycle (Georgetown, Tex.)\| PubMed ID: 19177002	2009
Determinants of response to epidermal growth factor receptor tyrosine kinase inhibition in squamous cell carcinoma of the head and neck. The Journal of pathology\| PubMed ID: 19197951	2009
In vitro assays for endothelial cell functions related to angiogenesis: proliferation, motility, tubular differentiation, and proteolysis. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 19301670	2009
The identification of novel PLC-gamma inhibitors using virtual high throughput screening. Bioorganic & medicinal chemistry\| PubMed ID: 19303309	2009
Changes in choline metabolism as potential biomarkers of phospholipase C{gamma}1 inhibition in human prostate cancer cells. Molecular cancer therapeutics\| PubMed ID: 19417158	2009
Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Molecular cancer therapeutics\| PubMed ID: 19584227	2009
Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. Journal of medicinal chemistry\| PubMed ID: 19610616	2009
Brk protects breast cancer cells from autophagic cell death induced by loss of anchorage. The American journal of pathology\| PubMed ID: 19661439	2009
The preclinical pharmacology and therapeutic activity of the novel CHK1 inhibitor SAR-020106. Molecular cancer therapeutics\| PubMed ID: 20053762	2010
Discovery of 4-amino-1-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)piperidine-4-carboxamides as selective, orally active inhibitors of protein kinase B (Akt). Journal of medicinal chemistry\| PubMed ID: 20151677	2010
Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Molecular cancer therapeutics\| PubMed ID: 20457619	2010
Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate. Journal of medicinal chemistry\| PubMed ID: 20565112	2010
Tumour-microenvironmental interactions: paths to progression and targets for treatment. Seminars in cancer biology\| PubMed ID: 20599506	2010
Bayesian estimation of changes in transverse relaxation rates. Magnetic resonance in medicine : official journal of the Society of Magnetic Resonance in Medicine / Society of Magnetic Resonance in Medicine\| PubMed ID: 20806382	2010
Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: Part 1. IDrugs : the investigational drugs journal\| PubMed ID: 21046522	2010
Metastasis and the Tumor Microenvironment: A Joint Metastasis Research Society-AACR Conference - Research on Metastasis: part 2. IDrugs : the investigational drugs journal\| PubMed ID: 21046523	2010
Preclinical pharmacology, antitumor activity, and development of pharmacodynamic markers for the novel, potent AKT inhibitor CCT128930. Molecular cancer therapeutics\| PubMed ID: 21191045	2011
Angiogenic functions of voltage-gated Na+ Channels in human endothelial cells: modulation of vascular endothelial growth factor (VEGF) signaling. The Journal of biological chemistry\| PubMed ID: 21385874	2011
Non-invasive in vivo imaging of vessel calibre in orthotopic prostate tumour xenografts. International journal of cancer. Journal international du cancer\| PubMed ID: 21469141	2012
Enhanced efficacy of IGF1R inhibition in pediatric glioblastoma by combinatorial targeting of PDGFRα/β. Molecular cancer therapeutics\| PubMed ID: 21659463	2011
Simple experimental and spontaneous metastasis assays in mice. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 21748685	2011
Ca2+ influx through reverse mode Na+/Ca2+ exchange is critical for vascular endothelial growth factor-mediated extracellular signal-regulated kinase (ERK) 1/2 activation and angiogenic funct... The Journal of biological chemistry\| PubMed ID: 21873429	2011
The aurora kinase inhibitor CCT137690 downregulates MYCN and sensitizes MYCN-amplified neuroblastoma in vivo. Molecular cancer therapeutics\| PubMed ID: 21885865	2011
Quantitative chemical proteomics reveals new potential drug targets in head and neck cancer. Molecular & cellular proteomics : MCP\| PubMed ID: 21955398	2011
Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing. Journal of medicinal chemistry\| PubMed ID: 22111927	2011
The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. The International journal of developmental biology\| PubMed ID: 22161825	2011
Flexible targeting of ErbB dimers that drive tumorigenesis by using genetically engineered T cells. Molecular medicine (Cambridge, Mass.)\| PubMed ID: 22354215	2012
Epigenetic disruption of cadherin-11 in human cancer metastasis. The Journal of pathology\| PubMed ID: 22374749	2012
Advances in establishment and analysis of three-dimensional tumor spheroid-based functional assays for target validation and drug evaluation. BMC biology\| PubMed ID: 22439642	2012
The HSP90 inhibitor NVP-AUY922 radiosensitizes by abrogation of homologous recombination resulting in mitotic entry with unresolved DNA damage. PloS one\| PubMed ID: 22523597	2012
Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. Journal of clinical immunology\| PubMed ID: 22526592	2012
Dependence of Wilms tumor cells on signaling through insulin-like growth factor 1 in an orthotopic xenograft model targetable by specific receptor inhibition. Proceedings of the National Academy of Sciences of the United States of America\| PubMed ID: 22529373	2012
Preclinical drug development for childhood cancer. Expert opinion on drug discovery\| PubMed ID: 22646826	2011
Kurt Hellmann D.M., D.Phil. Oxon. A happy 90th birthday! Clinical & experimental metastasis\| PubMed ID: 22695808	2012
AT13148 is a novel, oral multi-AGC kinase inhibitor with potent pharmacodynamic and antitumor activity. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22781553	2012
The ALK(F1174L) mutation potentiates the oncogenic activity of MYCN in neuroblastoma. Cancer cell\| PubMed ID: 22789543	2012
Erratum to: Kurt Hellmann D.M., D.Phil. Oxon. A happy 90th birthday! Clinical & experimental metastasis\| PubMed ID: 22872374	2012
CCT244747 is a novel potent and selective CHK1 inhibitor with oral efficacy alone and in combination with genotoxic anticancer drugs. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 22929806	2012
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the trea... Journal of medicinal chemistry\| PubMed ID: 23043539	2012
Discovery of 3-alkoxyamino-5-(pyridin-2-ylamino)pyrazine-2-carbonitriles as selective, orally bioavailable CHK1 inhibitors. Journal of medicinal chemistry\| PubMed ID: 23082860	2012
Two-dimensional vs. three-dimensional in vitro tumor migration and invasion assays. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 23436416	2013
Tumor spheroid-based migration assays for evaluation of therapeutic agents. Methods in molecular biology (Clifton, N.J.)\| PubMed ID: 23436417	2013
A novel serum protein signature associated with resistance to epidermal growth factor receptor tyrosine kinase inhibitors in head and neck squamous cell carcinoma. European journal of cancer (Oxford, England : 1990)\| PubMed ID: 23582742	2013
A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells. Journal of the American Chemical Society\| PubMed ID: 23796364	2013
Kurt Hellmann D. M., D. Phil. Oxon 1922–2013. Clinical & experimental metastasis\| PubMed ID: 23844428	2013
Dual blockade of the PI3K/AKT/mTOR (AZD8055) and RAS/MEK/ERK (AZD6244) pathways synergistically inhibits rhabdomyosarcoma cell growth in vitro and in vivo. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 23918606	2013
Mode of cell death induced by the HSP90 inhibitor 17-AAG (tanespimycin) is dependent on the expression of pro-apoptotic BAX. Oncotarget\| PubMed ID: 24185264	2013
Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1). Journal of medicinal chemistry\| PubMed ID: 24256217	2013
Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast cancer research : BCR\| PubMed ID: 24286369	2013
Preclinical evaluation of imaging biomarkers for prostate cancer bone metastasis and response to cabozantinib. Journal of the National Cancer Institute\| PubMed ID: 24634505	2014
HIF-1α-independent hypoxia-induced rapid PTK6 stabilization is associated with increased motility and invasion. Cancer biology & therapy\| PubMed ID: 25019382	2014
An open letter to the FDA and other regulatory agencies: Preclinical drug development must consider the impact on metastasis. Clinical cancer research : an official journal of the American Association for Cancer Research\| PubMed ID: 25278743	2009
Cancer-associated fibroblasts induce high mobility group box 1 and contribute to resistance to doxorubicin in breast cancer cells. BMC cancer\| PubMed ID: 25512109	2014
Exploring the biomechanical properties of brain malignancies and their pathologic determinants in vivo with magnetic resonance elastography. Cancer research\| PubMed ID: 25672978	2015
Discovery of potent, orally bioavailable, small-molecule inhibitors of WNT signaling from a cell-based pathway screen. Journal of medicinal chemistry\| PubMed ID: 25680029	2015